Science & Technology
Science and Technology
Science and Technology
Mon, January 12, 2009
CEO Philips Reviews CDEX Inc. 2008 Performance and Provides Insights for 2009
TUCSON, Ariz.--([ BUSINESS WIRE ])--CDEX Inc. (OTCBB:CEXI) CEO, Malcolm Philips, reviews CDEX's performance through 2008 and sets the stage for 2009 in the "CEO Corner" of the CDEX Web Site.
Mr. Philips reflected upon the start of CDEX in 2001 with three key employees embarking upon a mission to develop technology that made a difference in people's lives. Seven years later, CDEX's medication safety product line, ValiMed™, is saving lives in leading hospitals and its recently launched ID2 Meth Scanner™ is used by law enforcement agencies in the battle against illegal drugs. While the journey has, at times, been challenging, CDEX has built a culture based on its mission and fundamental beliefs.
Fiscal Year 2008 was another year of record revenue for the Company and Mr. Philips forecasted record revenue in FY2009, along with continued development of new products that save lives and protect the environment. For Mr. Philips' complete review, please go to the "CEO Corner" of the Management Briefing section of the CDEX Web Site ([ www.cdexinc.com ]).
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts or illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must raise additional funds as stated periodically in its SEC filings. For more information, visit [ www.cdexinc.com ].
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.
